Immunic, Inc. (IMUX), said Monday it has enrolled and randomized 200 patients, pre-specified in the protocol as sufficient to perform the main efficacy analysis of the phase 2 part of the CALVID-1 trial, for its selective oral DHODH inhibitor, IMU-838, in hospitalized patients with moderate coronavirus or COVID-19.
from RTT - Biotech https://ift.tt/384gTUM
via IFTTT
No comments:
Post a Comment